Human Milk Oligosaccharides

The HMO ingredient market sits at $0.35–0.4 billion today, on a path to ~$1.2–1.3 billion (combined TAM) by 2030. The investable story is what's happening inside it: a Chinese cost cohort that has closed to near-parity with Western mature plants at optimal-train scale, a Chinese commodity sales floor near $**·/kg that already carries healthy margin, a manufacturing-IP staircase running 2027→2035, and value migrating off the flagship 2'-FL into multi-HMO blends Chinese producers cannot yet supply to Western brands.

This brief makes the call in twenty-eight pages. The cost stack is built bottom-up at optimal-train scale; the IP cliff is read as a maintenance-fee schedule with named expiries; the regulatory access map is named structure × jurisdiction × player; the commercial supply battle is read against the public record (no Chinese-origin 2'-FL has surfaced in any verified Western multi-HMO product as of May 2026). The forward call is named, dated and falsifiable.

Authored by an operator with twenty years across the bio-based economy — global business-development leadership at DuPont Industrial Biosciences, CCO and CEO roles at specialty biotechs (including HMO), with transformation and exit; PhD and London Business School sustainability certification.

For investors and operators who need a defensible read on the category.

Decisive specific numbers — the Chinese commodity sales floor, the modelled COGS at single-train scale, the disclosed Chinese capacity, the post-2030 IP-cliff dates, the bear / base / bull TAM split — are blanked in this sample. They sit in the purchased brief.